摘要
目的观察上皮性卵巢癌组织趋化因子CXCL14与基质金属蛋白酶2 (MMP-2)表达。方法选取2015年5月至2017年12月,陕西省宁强县天津医院收治的上皮性卵巢癌患者78例,均手术留取其肿瘤组织(卵巢癌组),另外选取卵巢交界性肿瘤组织30例份(交界性肿瘤组),卵巢良性肿瘤组织20例份(良性肿瘤组),其中畸胎瘤7例,浆液性囊腺瘤5例,黏液性囊腺瘤4例,纤维瘤4例。采用免疫组化SP法检测三组CXCL14、MMP-2表达,分析卵巢癌CXCL14、MMP-2表达与患者临床病理参数的关系及CXCL14、MMP-2之间的关系。结果卵巢癌组CXCL14阳性表达率均低于交界性肿瘤组及良性肿瘤组,差异有统计学意义(χ~2=28.146、32.388,P<0.05),MMP-2阳性表达率均高于交界性肿瘤组及良性肿瘤组,差异有统计学意义(χ~2=5.524、9.568,P<0.05)。卵巢癌组织CXCL14表达与肿瘤TNM分期、淋巴结转移及腹水有关(χ~2=5.435、4.780、4.967,P<0.05),MMP-2表达与卵巢癌分化程度、TNM分期、淋巴结转移及腹水均有关(χ~2=8.969、22.772、19.855、18.332,P<0.05)。卵巢癌组织CXCL14、MMP-2表达呈负相关(r=-0.438,P<0.05)。结论卵巢癌组织趋化因子CXCL14低表达、MMP-2高表达,二者的表达变化参与卵巢癌的发生发展。
Objective To understand the expression and clinical significance of epithelial ovarian cancer tissue chemotactic factor CXCL14 and Matrix metalloproteinase 2. Methods Ovarian cancer tissues were collected from 78 patients with epithelial ovarian cancer(cancer group).Meanwhile,ovarian tissues from 30 cases with borderline ovarian tumors(borderline tumor group)and 20 cases with benign ovarian tumors(benign tumor group)were also collected.The expression levels of CXCL14 and MMP-2 in ovarian tissues were determined by the immunohistochemical SP method.The correlation between CXCL14 and MMP-2 and the clinical significance were analyzed and stated. Results The positive expression rate of CXCL14 in ovarian cancer group was significantly lower than the other two groups(χ^2=28.146,32.388,P〈0.05),while the positive expression rate of MMP-2 was significantly higher(χ^2=5.524,9.568,P〈0.05).The expression of CXCL14 in ovarian cancer was related to TNM stage,lymph node metastasis and ascites(χ^2=5.435,4.780,4.967,P〈0.05),while the expression of MMP-2 was related with tumor differentiation,TNM stage,lymph node metastasis and ascites(χ^2=8.969,22.772,19.855,18.332,P〈0.05).The expression of CXCL14 was negatively correlated with the expression of MMP-2 in ovarian cancer tissues(r=-0.438,P〈0.05). Conclusions The low expression of chemokine CXCL14 and high expression of MMP-2 in ovarian cancer tissues is closely related to the occurrence and development of ovarian cancer.
作者
赵艳芳
何訸
ZHAO Yan-fang;HE He(Department of Obstetrics and gynecology,Tianjin Hospital of Ningqiang,Ningqiang,Shaanxi 724400,China)
出处
《中国预防医学杂志》
CAS
CSCD
2018年第10期757-760,共4页
Chinese Preventive Medicine
基金
四川省软科学研究计划项目(2017ZR0063)